SUMMARY OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) GUIDELINE
In 2020, ASCO convened an expert panel to develop recommendations for the management of male breast cancer.5 In phase I, the ASCO Breast Cancer Advisory Group reported a high level of consensus in several areas where components of management were largely the same for men and women, including gene expression profile testing, primary surgery, chemotherapy, radiation therapy, and systemic therapy for advanced/metastatic disease. More specific guidance for breast surgery was not provided. In phase II, the goal was to address areas with limited data and/or a prior lack of consensus in areas where guidance from clinical trial data was desired. The guidelines in phase II offered 12 recommendations addressing 10 clinical questions on key aspects of the management of male breast cancer. These aspects can be loosely grouped into four areas: genetic testing, endocrine therapy (ET), targeted therapy administration, and post-treatment surveillance. In this section, we summarize recommendations from the phase II portion of the guideline that exceeded 75% panel member consensus.All males with breast cancer should be offered germline genetic testing and counseling.Men with early-stage hormone receptor-positive (HR+) breast cancer should be treated with tamoxifen for 5 years. If they are tolerating ET at 5 years and are still at high risk of recurrence, they should be offered 5 additional years.A gonadotropin-releasing hormone (GnRH) agonist/antagonist and an aromatase inhibitor (AI) should be used if tamoxifen is contraindicated.Bone-modifying agents should not be used to prevent recurrence but can be used to prevent/treat osteoporosis.Men with advanced or metastatic HR+ breast cancer should be offered ET as first-line therapy, with the addition of fulvestrant as an option, except in cases of visceral crisis or rapidly progressive disease.Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors can be used in men with high risk of recurrence.6If a patient develops progression/recurrence of disease while receiving ET, they should be offered an alternative agent.
Testosterone/androgen supplementation should not be used for the management of ET toxicity.
For men with advanced or metastatic breast cancer, targeted therapies guided by human epidermal growth factor receptor 2 (HER2) receptor status, programmed death ligand 1 expression, PIK3CA mutation, and germline BRCA pathogenic/likely pathogenic variants (PVs) should be administered per the same indications/combinations that are offered to women.
Men should be educated about symptoms of recurrence. Continuity of care for patients with breast cancer is recommended and should be performed by providers experienced in the surveillance of breast cancer and the breast examination.
Ipsilateral annual mammogram should be offered to men with a history of breast cancer treated with lumpectomy, if technically feasible, regardless of genetic predisposition. Contralateral annual mammogram may be offered to men with a history of breast cancer and a PV predisposing them to breast cancer.Breast magnetic resonance imaging (MRI) is not routinely recommended.
Contralateral annual mammogram may be offered to men with a history of breast cancer and a PV predisposing them to breast cancer.
Breast magnetic resonance imaging (MRI) is not routinely recommended.
There were two draft recommendations that did not exceed the required 75% consensus agreement threshold and were therefore not included in the final guidelines. The first was regarding contralateral annual mammography in men without a predisposing variant and the second was the use of chemoprevention in high-risk males.
RECOMMENDATIONS FROM OTHER PROFESSIONAL SOCIETIES, NEW INFORMATION, AND FURTHER COMMENTS REGARDING BREAST SURGERY
Many professional societies have developed guidelines for identifying and treating male breast cancer. The American College of Radiology (ACR) recommends ultrasonography (US) as the initial test for men <25 years of age who have an indeterminate palpable mass.7 For men ≥25 years of age or those with questionable findings on physical examination, mammography is recommended as the initial diagnostic test, with US recommended if the mammographic findings are inconclusive or suggestive of cancer. Based on low rates of contralateral breast cancer in male survivors, ASCO recommends reserving contralateral mammography for those with known PVs.
The 2020 ASCO guideline indicates that primary surgery for men with breast cancer is largely the same as for women. The 2024 National Comprehensive Cancer Network (NCCN) guidelines acknowledge that few males have been included in breast cancer clinical trials.4 Their recommendations, extrapolated from findings of clinical trials focusing on breast cancer in females, include offering breast-conservation surgery (BCS) in appropriate candidates. There are also some small retrospective studies that indicate comparable long-term survival when treatment protocols are similar to female breast cancer.8 Provided that the tumor-to-breast ratio and location are amendable to BCS, we fully support this as a surgical option for males with breast cancer.
Traditionally, a mastectomy has been the mainstay of surgical treatment for males with breast cancer, likely due to clinical presentation and more advanced disease states. The use of nipple-sparing mastectomy (NSM), while certainly gaining traction in the setting of female breast cancers, has not been met with the same enthusiasm in male breast cancer. Very few cancer societies have set out definitive guidelines on NSM, even in females. Most males with breast cancer are not NSM candidates based on disease presentation and tumor location. If an appropriately selected patient is deemed an NSM candidate and the operation is in line with his oncologic and cosmetic goals, NSM can be considered after multidisciplinary discussion. The use of routine contralateral prophylactic mastectomy (CPM) is not advised.
The NCCN recommendations, extrapolated from findings of clinical trials focusing on breast cancer in females, include offering axillary staging in those who are clinically node-negative. The lack of men in these trials suggests that the findings from seminal work surrounding axillary deescalation may not be applicable to males with breast cancer. However, sentinel lymph node biopsy (SLNB) is the standard approach for women with clinically negative axilla, and this approach is both feasible and highly accurate for men with breast cancer who present with a clinically negative axilla.2 A recently published non-inferiority trial compared SLNB alone with axillary lymph node dissection (ALND) in the upfront surgery setting for patients with nodal macrometastases. This trial included males (although only 10 were enrolled), furthering the acceptance that SLNB should be applied to male breast cancer patients when appropriate.9 For males with breast cancer who are clinically node-positive at presentation, the same therapeutic strategies and potential nodal downstaging should be offered as is done for their female counterparts. This recommendation is in line with the ASCO and NCCN guidelines addressing that systemic therapy should be offered in the neoadjuvant setting based on tumor subtype and stage at diagnosis.4,5 Not only does this help identify treatment-resistant disease, it also assists with axillary downstaging. We fully support offering an SLNB when appropriate in this setting, provided that the axilla demonstrates a favorable clinical and pathologic response.
In the adjuvant setting, the NCCN and American Society for Radiation Oncology both endorse the use of radiation therapy in appropriate candidates.4,10 In a 2018 meta-analysis of 29 studies and 10,965 men diagnosed with breast cancer (of whom 23% were T4, 50% were node-positive, and 93% underwent mastectomy), 64% underwent adjuvant radiation, which was associated with improved outcomes.11 These data support the use of post-mastectomy radiation with similar indications as seen in female breast cancer. Using the National Cancer Database (NCDB), which identified over 10,000 male breast cancers over a 10-year period, the authors reported that breast-conserving therapy (BCT) was performed in 24% of patients. Of those who underwent a lumpectomy, 70% received radiotherapy. In this study, the receipt of radiotherapy was associated with improved overall survival.30
The use, duration, and recommendations for adjuvant radiation therapy in males who undergo BCT should be similar to those recommendations for females with breast cancer, with one exception being partial breast irradiation (PBI) as males were not included in the consensus guidelines.10 Anatomical considerations after BCT should be considered and PBI may not be reasonable.
Most professional societies recommend that all males with breast cancer be offered genetic testing.4,5,12 If a male was to test positive for a BRCA PV, which confers a 7% lifetime risk of breast cancer, the NCCN encourages annual clinical breast examination to start at age 35 years, and to consider annual mammographic screening in men with gynecomastia starting at age 50 years, or 10 years before the earliest known male breast cancer.4
Annual post-treatment mammography for men who have undergone BCS is recommended by ASCO, although is not specifically addressed by the ACR or NCCN.5 There appears to be an underutilization of surveillance mammography for men with a history of breast cancer. Interestingly, a recent retrospective review demonstrated that those patients who undergo radiation following their cancer operations were found to be more likely to undergo routine surveillance.13 These results suggest that those individuals are more likely to undergo guideline-concordant care. As the use of BCS in men and post-treatment surveillance increases, updated recommendations will likely follow. Until then, post-treatment annual mammography should be offered based on clinical suspicion, patient and physician preference, and institutional policy. Routine breast MRI is not recommended in men with a history of breast cancer. The recommendation is due, in part, to (1) the relatively small amount of breast tissue present in most men; (2) the lack of data demonstrating survival benefit; and (3) the potential for false positives.5 Enhanced high-risk screening (i.e. alternating mammogram and MRI) is also not recommended for high-risk men (including those with a PV in BRCA2).
The lack of men in breast cancer trials means that the findings from seminal work around personalization of care using genomic testing (such as Oncotype score) are potential ways forward, although with some uncertainty regarding applicability. It appears that in general, the data surrounding oncotype score are promising.2,14 Additional recommendations for systemic therapy will continue to evolve when the results of several ongoing studies, both those specific to men with breast cancer (Table 1) and those that permit enrollment of men (Table 2), are available. Some of these trials are evaluating response to different combinations of ET and CDK 4/6 inhibitors in the neoadjuvant (ETHAN15), adjuvant (MALE16, lidERA17), and advanced/metastatic (ADELA18) settings. Other studies have, or are investigating, the use of more novel targets such as the androgen receptor (CLARITY-0119), hyaluronan (NCT275359520) and HER3 (NCT0298034121). Whether the treatment of male breast cancer evolves to include novel combinations of drugs exploiting the high proportion of HR+ breast cancer seen in this population, or the use of agents against novel targets, the inclusion of males in ongoing trials is paramount to understanding this rare but important disease.
CONCLUSIONS
The 2020 ASCO guideline reflects a thoughtful approach for the management of male breast cancer, highlighting similarities and differences in management when compared with females. It is important to include men in ongoing and upcoming breast cancer trials, not only systemic therapy but also locoregional therapy trials, to continue to define optimal therapies for male breast cancer.
AW
Dr. Austin Williams
Surgery · Breast Surgical OncologyFox Chase Cancer Centeraustin